Search

everythinglearnresearchcommunity

for

Search:↓

Oral finasteride and dutasteride may negatively affect erectile function in rats.

Different substances that activate or block the androgen receptor can affect male development and treat conditions like prostate cancer.

Finasteride treats baldness but may cause lasting sexual side effects.

Cernitin™, a pollen extract, was found to significantly reduce pain and inflammation in rats with chronic prostatitis, suggesting it could be a useful alternative to certain anti-inflammatory drugs.

RV3466F lotion significantly reduces hair loss and improves acute telogen effluvium.

Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.

The research found that androgens help control blood flow in the rat prostate through a specific binding site.

Menopause is a clear hormonal transition in women, while men experience a gradual testosterone decline, with some needing lifestyle changes and targeted therapy.

Testosterone with finasteride improved muscle and bone health in men with spinal cord injury.

Kolaviron and quercetin may help treat prostate issues.

Testosterone replacement therapy helps manage deficiency and has various methods, but requires careful monitoring to avoid side effects.

Hormones, especially testosterone and DHT, are key for penis development and function, and testosterone therapy may help with erectile dysfunction in those with low levels.

Male sexual differentiation is regulated independently, while female differentiation occurs in an androgenic environment, affecting conditions like congenital adrenal hyperplasia.

A genetic test can identify people at risk of male pattern baldness early, allowing for quicker treatment.

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

The conclusion is that women are heavily affected by autoimmune skin diseases, face significant challenges, and need better research, treatments, and healthcare policies.

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.

Metformin may lower PSA levels, possibly affecting prostate cancer development.

Finasteride reduces prostate cancer risk but may affect ejaculatory volume and requires careful consideration for young men.

There's no link between hair loss type androgenic alopecia and benign prostatic hyperplasia, but early hair loss and family history can mean more severe alopecia.

Combination therapy for BPH is more effective in certain men but may not be cost-effective due to minimal impact and potential side effects.

CT scans can find serious prostate cancer even when PSA levels are low.

Long-term finasteride use may lead to earlier use of ED medication and lower prostate cancer diagnosis rates.

Hair loss can be an early sign of prostate enlargement.

Testosterone treatment for older men can have short-term benefits, but long-term risks are unclear, requiring careful evaluation and monitoring.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.

SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.

Prostate cancer can progress even with low testosterone due to internal hormone production in the tumor.

Finasteride reduces prostate size and symptoms with few side effects.